Is PROK or NRXP more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. Company Net Margins Return on Equity Return on Assets ProKidney -8,131.50% N/A -21.39% NRx Pharmaceuticals N/A N/A -202.92%

Does the media favor FDMT or NRXP?

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 6 mentions for NRx Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 0.42 beat NRx Pharmaceuticals' score of 0.32 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TLRY or NRXP?

In the previous week, Tilray Brands had 15 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 21 mentions for Tilray Brands and 6 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.68 beat NRx Pharmaceuticals' score of 0.32 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 7 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STRO or NRXP more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -154.21% N/A -69.20% NRx Pharmaceuticals N/A N/A -202.92%

Does the media refer more to STRO or NRXP?

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat NRx Pharmaceuticals' score of 0.32 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, EIKN or NRXP?

Eikon Therapeutics has higher earnings, but lower revenue than NRx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A NRx Pharmaceuticals $1.23M 117.82 -$28.62M -$1.09 N/A

Is EIKN or NRXP more profitable?

Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A NRx Pharmaceuticals N/A N/A -202.92%

Does the media prefer EIKN or NRXP?

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 4 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.89 beat NRx Pharmaceuticals' score of 0.32 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NRx Pharmaceuticals (NRXP) Competitors

$4.00 +0.27 (+7.24%)

Closing price 04:00 PM Eastern

Extended Trading

$3.90 -0.10 (-2.38%)

As of 05:05 PM Eastern

Compare

NRXP vs. PROK, FDMT, TLRY, STRO, and EIKN

Should you buy NRx Pharmaceuticals stock or one of its competitors? MarketBeat compares NRx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NRx Pharmaceuticals include ProKidney (PROK), 4D Molecular Therapeutics (FDMT), Tilray Brands (TLRY), Sutro Biopharma (STRO), and Eikon Therapeutics (EIKN). These companies are all part of the "pharmaceutical products" industry.

How does NRx Pharmaceuticals compare to ProKidney?

ProKidney (NASDAQ:PROK) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

NRx Pharmaceuticals has higher revenue and earnings than ProKidney. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	641.45	-$68.99M	-$0.53	N/A
NRx Pharmaceuticals	$1.23M	117.82	-$28.62M	-$1.09	N/A

ProKidney has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 5 more articles in the media than ProKidney. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat NRx Pharmaceuticals' score of 0.32 indicating that ProKidney is being referred to more favorably in the media.

Company	Overall Sentiment
ProKidney	Very Positive
NRx Pharmaceuticals	Neutral

ProKidney presently has a consensus target price of $7.40, indicating a potential upside of 291.53%. NRx Pharmaceuticals has a consensus target price of $38.25, indicating a potential upside of 856.25%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NRx Pharmaceuticals has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
NRx Pharmaceuticals	N/A	N/A	-202.92%

Summary

ProKidney beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

NRx Pharmaceuticals has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.90	-$140.11M	-$2.57	N/A
NRx Pharmaceuticals	$1.23M	117.82	-$28.62M	-$1.09	N/A

NRx Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. NRx Pharmaceuticals' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, 4D Molecular Therapeutics had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 6 mentions for NRx Pharmaceuticals. 4D Molecular Therapeutics' average media sentiment score of 0.42 beat NRx Pharmaceuticals' score of 0.32 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

4D Molecular Therapeutics presently has a consensus target price of $29.88, suggesting a potential upside of 131.95%. NRx Pharmaceuticals has a consensus target price of $38.25, suggesting a potential upside of 856.25%. Given NRx Pharmaceuticals' higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

4D Molecular Therapeutics beats NRx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Tilray Brands has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Tilray Brands presently has a consensus target price of $11.50, indicating a potential upside of 149.46%. NRx Pharmaceuticals has a consensus target price of $38.25, indicating a potential upside of 856.25%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. NRx Pharmaceuticals' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
NRx Pharmaceuticals	N/A	N/A	-202.92%

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tilray Brands had 15 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 21 mentions for Tilray Brands and 6 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.68 beat NRx Pharmaceuticals' score of 0.32 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	7 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48M	2.55	-$2.19B	-$13.65	N/A
NRx Pharmaceuticals	$1.23M	117.82	-$28.62M	-$1.09	N/A

Summary

NRx Pharmaceuticals beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Sutro Biopharma currently has a consensus target price of $52.44, suggesting a potential upside of 57.25%. NRx Pharmaceuticals has a consensus target price of $38.25, suggesting a potential upside of 856.25%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sutro Biopharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
NRx Pharmaceuticals	N/A	N/A	-202.92%

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Sutro Biopharma. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat NRx Pharmaceuticals' score of 0.32 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has lower revenue, but higher earnings than Sutro Biopharma. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$99.61M	5.55	-$191.09M	-$11.04	N/A
NRx Pharmaceuticals	$1.23M	117.82	-$28.62M	-$1.09	N/A

Summary

Sutro Biopharma and NRx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Eikon Therapeutics has higher earnings, but lower revenue than NRx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
NRx Pharmaceuticals	$1.23M	117.82	-$28.62M	-$1.09	N/A

Eikon Therapeutics currently has a consensus price target of $25.20, indicating a potential upside of 97.80%. NRx Pharmaceuticals has a consensus price target of $38.25, indicating a potential upside of 856.25%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

4.3% of NRx Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 4 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.89 beat NRx Pharmaceuticals' score of 0.32 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NRx Pharmaceuticals beats Eikon Therapeutics on 6 of the 9 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXP vs. The Competition

Export

Metric	NRx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$144.92M	$3.06B	$6.84B	$12.44B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	-3.67	19.67	25.83	24.36
Price / Sales	117.82	345.26	540.60	96.08
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	-7.41	4.25	10.98	6.49
Net Income	-$28.62M	$64.45M	$3.57B	$336.61M
7 Day Performance	2.56%	4.16%	3.05%	0.91%
1 Month Performance	-9.50%	1.43%	0.72%	-0.35%
1 Year Performance	16.96%	34.06%	36.81%	31.28%

NRx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXP NRx Pharmaceuticals	2.6161 of 5 stars	$4.00 +7.2%	$38.25 +856.3%	+9.1%	$144.92M	$1.23M	N/A	2	Gap Up
PROK ProKidney	2.186 of 5 stars	$1.82 -0.3%	$7.40 +307.7%	+173.7%	$548.24M	$890K	N/A	3	Positive News
FDMT 4D Molecular Therapeutics	1.87 of 5 stars	$10.28 -1.4%	$29.88 +190.6%	+202.1%	$540.84M	$85.21M	N/A	120	News Coverage
TLRY Tilray Brands	2.8535 of 5 stars	$4.57 -0.5%	$11.50 +151.8%	+15.8%	$528.20M	$210.48M	N/A	2,842
STRO Sutro Biopharma	3.1457 of 5 stars	$31.30 -0.8%	$52.44 +67.5%	+315.8%	$525.32M	$99.61M	N/A	240	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. PROK, FDMT, TLRY, STRO, and EIKN

How does NRx Pharmaceuticals compare to ProKidney?

Summary

How does NRx Pharmaceuticals compare to 4D Molecular Therapeutics?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Summary

How does NRx Pharmaceuticals compare to Sutro Biopharma?

Summary

How does NRx Pharmaceuticals compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. PROK, FDMT, TLRY, STRO, and EIKN

How does NRx Pharmaceuticals compare to ProKidney?

Which has better earnings & valuation, PROK or NRXP?

Which has more risk & volatility, PROK or NRXP?

Does the media favor PROK or NRXP?

Do analysts prefer PROK or NRXP?

Do institutionals & insiders have more ownership in PROK or NRXP?

Is PROK or NRXP more profitable?

Summary

How does NRx Pharmaceuticals compare to 4D Molecular Therapeutics?

Which has higher earnings and valuation, FDMT or NRXP?

Is FDMT or NRXP more profitable?

Does the media favor FDMT or NRXP?

Do institutionals and insiders hold more shares of FDMT or NRXP?

Which has more risk & volatility, FDMT or NRXP?

Do analysts recommend FDMT or NRXP?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Which has more risk and volatility, TLRY or NRXP?

Do analysts rate TLRY or NRXP?

Is TLRY or NRXP more profitable?

Do insiders and institutionals believe in TLRY or NRXP?

Does the media favor TLRY or NRXP?

Which has preferable valuation and earnings, TLRY or NRXP?

Summary

How does NRx Pharmaceuticals compare to Sutro Biopharma?

Do analysts recommend STRO or NRXP?

Which has more risk & volatility, STRO or NRXP?

Is STRO or NRXP more profitable?

Do insiders & institutionals hold more shares of STRO or NRXP?

Does the media refer more to STRO or NRXP?

Which has better valuation and earnings, STRO or NRXP?

Summary

How does NRx Pharmaceuticals compare to Eikon Therapeutics?

Which has better valuation & earnings, EIKN or NRXP?

Do analysts rate EIKN or NRXP?

Do institutionals and insiders hold more shares of EIKN or NRXP?

Is EIKN or NRXP more profitable?

Does the media prefer EIKN or NRXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools